Carmustine

Lymphoma, Non-Hodgkin, Glioblastoma, Multiple Myeloma + 9 more
Treatment
20 Active Studies for Carmustine

What is Carmustine

CarmustineThe Generic name of this drug
Treatment SummaryAlkylating antineoplastic is a type of medication used to treat cancer by targeting cells in any stage of the cell cycle. It is most often used to treat brain tumors and other types of cancer. The use of this drug may increase the risk of developing cancer.
Gliadelis the brand name
image of different drug pills on a surface
Carmustine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gliadel
Carmustine
1996
17

Effectiveness

How Carmustine Affects PatientsCarmustine is a medication used to treat brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. It works by affecting both DNA and RNA structures, and is not related to any other alkylators. It may also affect key enzymes by attaching to proteins in the body.
How Carmustine works in the bodyCarmustine works by blocking DNA and RNA production which prevents the body from making proteins. It also binds to and changes an enzyme which leads to cell death.

When to interrupt dosage

The recommended dosage of Carmustine is contingent upon the identified condition, like Glioblastoma, Recently Identified High Grade Glioma (HGG) and Medulloblastomas. Dosage is subject to the technique of delivery, as presented in the following table.
Condition
Dosage
Administration
Glioblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Metastatic Brain Tumors
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Ependymoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Lymphoma, Non-Hodgkin
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Glioblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Multiple Myeloma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Hodgkin Disease
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Medulloblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Glioma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Brain Stem Gliomas
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Astrocytoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Mycosis Fungoides
, 7.7 mg, 100.0 mg, 10.0 mg/mL
Intracavitary, Wafer, , Wafer - Intracavitary, Intralesional, Wafer - Intralesional, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous

Warnings

Carmustine Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Carmustine may interact with Pulse Frequency
There are 20 known major drug interactions with Carmustine.
Common Carmustine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Aldosterone.
Carmustine Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats and mice is 20mg/kg and 45mg/kg respectively. Common side effects are low white blood cell count, low platelet count, and nausea. Severe toxic effects can include scarring of the lungs (20-0%) and damage to the bone marrow.
image of a doctor in a lab doing drug, clinical research

Carmustine Novel Uses: Which Conditions Have a Clinical Trial Featuring Carmustine?

166 active trials are currently testing the potential of Carmustine in managing Newly Diagnosed High Grade Glioma (HGG), Hodgkin Disease and Non-Hodgkin Lymphoma.
Condition
Clinical Trials
Trial Phases
Medulloblastoma
0 Actively Recruiting
Metastatic Brain Tumors
56 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1, Phase 4
Hodgkin Disease
2 Actively Recruiting
Phase 2, Phase 1
Lymphoma, Non-Hodgkin
0 Actively Recruiting
Glioma
0 Actively Recruiting
Astrocytoma
0 Actively Recruiting
Ependymoma
0 Actively Recruiting
Glioblastoma
2 Actively Recruiting
Phase 1
Mycosis Fungoides
0 Actively Recruiting
Brain Stem Gliomas
1 Actively Recruiting
Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Glioblastoma
61 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3

Carmustine Reviews: What are patients saying about Carmustine?

3Patient Review
4/14/2016
Carmustine for Malignant Brain Tumor Glioblastoma
I received this treatment every two weeks and saw my blood counts and platelets drop. Despite this, the tumor continued to grow.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about carmustine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is a long term side effect of carmustine?

"Carmustine may cause serious pneumonitis and pulmonary fibrosis (a scarring and stiffening of the lung tissue)

Carmustine may cause serious inflammation of the lungs and scarring of the lung tissue, which can make the lungs stiff and difficult to breathe. These problems can develop months to years after treatment is completed and may be more common in people with pre-existing lung conditions."

Answered by AI

What type of drug is carmustine?

"Carmustine is a medication that belongs to a group of drugs called alkylating agents. These drugs work by preventing the cancer cells from growing and multiplying."

Answered by AI

What is carmustine used to treat?

"Carmustine is a chemotherapy drug, also known by its brand name BCNU. It is a treatment for brain tumours, non Hodgkin's lymphoma and Hodgkin's lymphoma. For adults with a type of brain tumour called glioma, doctors might use a form of carmustine called Gliadel wafers."

Answered by AI

Clinical Trials for Carmustine

Image of Washington University School of Medicine in St Louis, United States.

NT-I7 + CAR-T Therapy for Multiple Myeloma

18+
All Sexes
St Louis, MO
CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation Antigen (BCMA). While BCMA CAR-T cell-treated patients achieve an excellent overall response rate, their response is often not durable. NT-I7 promotes CAR-T cell expansion and efficacy in pre-clinical lymphoma models. In patients receiving CD19-directed CAR-T therapy for lymphoma, NT-I7 augmented CAR-T expansion while being safe and tolerable. The impact of NT-I7 on BCMA CAR-T cells in multiple myeloma is unknown. This is a two-arm, double blind, placebo-controlled, randomized, single-site phase Ib study testing the safety and toxicity of adding NT-I7 to BCMA CAR-T therapy in patients with relapsed and refractory multiple myeloma. The hypothesis is that NT-I7 will promote CAR-T expansion and persistence which will enhance clearance of MM, while maintaining a favorable safety and toxicity profile. Patients receiving standard of care BCMA CAR-T (Cilta-cel) will be randomized to either NT-I7 or placebo. Correlative studies will evaluate CAR-T cell expansion, persistence, immune-phenotype, function and correlate with clinical outcomes.
Phase 1
Waitlist Available
Washington University School of MedicineMichael Slade, M.D., M.S.C.INeoImmuneTech
Image of Mayo Clinic in Phoenix, United States.

MT-125 for Glioblastoma

18+
All Sexes
Phoenix, AZ
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard of care treatment. Initially, participants with newly diagnosed glioblastoma will be given different doses of MT-125 in combination with radiotherapy (RT) with the goal of identifying the highest tolerated dose. Up to 36 people with glioblastoma who are at least18 years old are being invited to join this study. MT-125 is a type of study treatment which acts on cancer cells in the brain to destroy them. It will be administered on the same day as your standard of care radiotherapy because it is also designed to help radiotherapy work better. However, this is the first time MT-125 will be studied in humans. Therefore, the use is considered investigational. If you would like more details about MT-125 in glioblastoma participants, please ask the Study Doctor. You will be among the first participants with glioblastoma to receive this study treatment. Its safety and effectiveness have not yet been established in humans. Thus, we do not know whether it will work for you. Your condition may improve, may get worse, or there may be no change. The selected participant population-individuals newly diagnosed with histologically and/or molecularly confirmed IDH wild-type, MGMT-unmethylated glioblastoma-represents those least likely to experience safety concerns or adverse events related to the study treatment, and most likely to derive therapeutic benefit. There are certain tests/questions you must complete to find out if you meet the requirements to be in the study. If you do not meet these requirements, you cannot take part in the study. If this happens, you can talk to your Study Doctor about other options.
Phase 1
Waitlist Available
Mayo Clinic (+2 Sites)Myosin Therapeutics Inc.
Have you considered Carmustine clinical trials? We made a collection of clinical trials featuring Carmustine, we think they might fit your search criteria.Go to Trials
Have you considered Carmustine clinical trials? We made a collection of clinical trials featuring Carmustine, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Intensified Radiation Therapy for Brain Cancer

65+
All Sexes
Boston, MA
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs. To address these challenges, prior work has evaluated the feasibility of hypofractionation, a treatment approach delivering fewer, larger radiation dosages over a shorter time period. Common hypofractionated regimens deliver a lower biologically equivalent radiation dose than the conventional regimens used for younger adults. Whether dose escalated hypofractionation can further improve outcomes in older adults remains unclear. This will be a hybrid randomized control trial comparing the efficacy and safety of dose-escalated and standard hypofractionated radiotherapy among older adults with newly-diagnosed glioblastoma compared to standard three-week course. This research study involves the administration of radiation therapy. Radiation will either be delivered at the standard daily dose or at an increased daily dose over a three weeks course of radiation treatment. Research study procedures will include a screening evaluation to assess eligibility, as well as clinical visits for radiation delivery and to assess symptoms during treatment and at scheduled follow-up times. Participants will be randomly assigned to one of the two arms of the trial: 1. Standard hypofractionated radiation over 3 weeks 2. Dose-escalated hypofractionated radiation over 3 weeks
Phase 2
Recruiting
Brigham and Women's Hospital (+2 Sites)
Image of Duke University Health System in Durham, United States.

Selinexor + Antibody for Multiple Myeloma

18+
All Sexes
Durham, NC
The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific antibody therapy. The investigators will enroll 27 patients with RRMM who are receiving commercial bispecific antibody therapy. Patients will be on treatment for 12 months or until disease progression, and will be followed for 24 months. Study assessments include completing a drug diary, having a safety check in call, and have history, clinical assessments, and labs taken. Twenty-seven patients will provide 80% power in a one-sample chi square test for a proportion assuming that the rate of negative MRD at 10-5 at 12 months post bispecific antibody therapy is 25% in historical control and 50% in the SEL+bispecific antibody experimental treatment group, under a one-sided 5% significance level.
Phase 2
Recruiting
Duke University Health SystemYubin Kang, MD
Image of Arizona Cancer Center at UMC North/University Medical Center in Tucson, United States.

Tarlatamab + Radiation for Cancer

18 - 99
All Sexes
Tucson, AZ
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. III) If sequential tarlatamab and radiation is not deemed safe, we would allow for continued enrollment to assess efficacy of drug sans radiation treatment, enriching for tumors not of small cell lung cancer histology and allowing for patients without sites amenable to RT. A nested phase II study will attempt to assess for ORR and safety of study intervention amongst tumors not of small cell lung cancer histology.
Phase 1 & 2
Recruiting
Arizona Cancer Center at UMC North/University Medical CenterCharles Hsu, MDAmgen
Image of City of Hope in Duarte, United States.

Dendritic Cell Immunotherapy for Glioblastoma

18+
All Sexes
Duarte, CA
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: \- Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation
Phase 2
Recruiting
City of Hope (+8 Sites)Diakonos Oncology Corporation
Have you considered Carmustine clinical trials? We made a collection of clinical trials featuring Carmustine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security